Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Actin-binding LIM protein 1 (ABLIM1) is a multi-domain protein consisting of four LIM domains—protein-protein interaction modules—plus a villin headpiece (VHP) for actin filament binding, and a coiled-coil domain. It mediates the formation and maintenance of cortical actin networks, impacts cell migration, prevents mechanical tension-induced cell blebbing, and acts as a scaffold for signal transduction. As an E3 ubiquitin ligase, it modulates NF-κB signaling by promoting the ubiquitination and degradation of IκBα, thereby activating gene expression programs involved in cancer progression and cell survival. ABLIM1 plays a regulatory role in osteoclastogenesis and bone metabolism via the PI3K/Akt/Rac1 axis. Its expression is tissue-specific, seen notably in retina, brain, muscle, and implicated in several diseases, with contrasting roles in tumorigenesis depending on tumor type.
For drugs/inhibitors: targeting its E3 ligase activity could reduce NF-κB activation and downstream oncogenic signals. Targeting its actin-binding function may regulate cell motility and cytoskeletal dynamics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Actin-binding LIM protein 1 (ABLIM1).